| CLDX Stock | | | USD 27.44 0.45 1.61% |
Founder
Dr. Tibor Keler, Ph.D., serves as Executive Vice President and Chief Scientific Officer of Celldex Therapeutics Inc. since July 30, 2014. Since, May 2003, Dr. Keler has held a number of positions with Celldex, including a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. While at Medarex, he was responsible for the development of Celldex technology and products, as well as for the preclinical development and testing of numerous Medarex products now in clinical trials since 2014.
| Age | 65 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | Perryville III Building, Hampton, NJ, United States, 08827 |
| Phone | 908 200 7500 |
| Web | https://www.celldex.com |
Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
Celldex Therapeutics Management Efficiency
The company has return on total asset
(ROA) of
(0.1973) % which means that it has lost $0.1973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.2984) %, meaning that it created substantial loss on money invested by shareholders. Celldex Therapeutics' management efficiency ratios could be used to measure how well Celldex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.34 in 2024.
Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Celldex Therapeutics'
Total Assets are fairly stable compared to the past year.
Total Current Assets is likely to rise to about 453.3
M in 2024, whereas
Non Current Assets Total are likely to drop slightly above 31
M in 2024.
Celldex Therapeutics currently holds 2.54
M in liabilities with Debt to Equity
(D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Celldex Therapeutics has a current ratio of 12.04, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Celldex Therapeutics' use of debt, we should always consider it together with its cash and equity.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey. Celldex Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 132 people. Celldex Therapeutics (CLDX) is traded on NASDAQ Exchange in USA. It is located in Perryville III Building, Hampton, NJ, United States, 08827 and employs 160 people. Celldex Therapeutics is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Celldex Therapeutics Leadership Team
Elected by the shareholders, the Celldex Therapeutics' board of directors comprises two types of representatives: Celldex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Celldex. The board's role is to monitor Celldex Therapeutics' management team and ensure that shareholders' interests are well served. Celldex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Celldex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patrick Till, Senior Communications | |
| Prof Schlessinger, CoFounder Board | |
| Diane MD, Senior Officer | |
| Ronald Pepin, Chief Bus. Officer and Sr. VP | |
| Sam CPA, CFO, VP | |
| Sam Martin, CFO, Senior Vice President | |
| Margo MD, Senior Affairs | |
| Sarah Cavanaugh, Vice President Investor Relations & Corporate Communications | |
| Freddy Esq, Senior Counsel | |
| Elizabeth Crowley, Senior Vice President Chief Product Development Officer | |
| Richard Wright, Chief VP | |
| Anthony MBA, President, Founder | |
| Tibor Keler, Founder, Chief Scientific Officer and Executive VP | |
Celldex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Celldex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Celldex Stock Analysis
When running Celldex Therapeutics' price analysis, check to
measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to
predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.